These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12735407)

  • 1. Cost analysis of Down syndrome screening in advanced maternal age.
    Hartnett J; Borgida AF; Benn PA; Feldman DM; DeRoche ME; Egan JF
    J Matern Fetal Neonatal Med; 2003 Feb; 13(2):80-4. PubMed ID: 12735407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
    Cusick W; Vintzileos AM
    J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum alpha-fetoprotein screening for Down syndrome: economic considerations.
    Swint JM; Greenberg F
    Am J Med Genet; 1988 Sep; 31(1):231-45. PubMed ID: 2464933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome.
    Shackley P; McGuire A; Boyd PA; Dennis J; Fitchett M; Kay J; Roche M; Wood P
    J Public Health Med; 1993 Jun; 15(2):175-84. PubMed ID: 7688977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-trimester Down syndrome screening in women younger than 35 years old and cost-effectiveness analysis in Taiwan population.
    Chou CY; Hsieh FJ; Cheong ML; Lee FK; She BQ; Tsai MS
    J Eval Clin Pract; 2009 Oct; 15(5):789-96. PubMed ID: 19811590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down syndrome prevention program in a population with an older maternal age.
    Shohat M; Legum C; Romem Y; Borochowitz Z; Bach G; Goldman B
    Obstet Gynecol; 1995 Mar; 85(3):368-73. PubMed ID: 7862374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
    Kristoffersson U; Nørgaard-Pedersen B
    Lakartidningen; 1995 Mar; 92(12):1205-6, 1211-2. PubMed ID: 7535873
    [No Abstract]   [Full Text] [Related]  

  • 9. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis.
    Cuckle H; Benn P; Pergament E
    Prenat Diagn; 2013 Jul; 33(7):636-42. PubMed ID: 23674341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age.
    Nakata N; Wang Y; Bhatt S
    Prenat Diagn; 2010 Mar; 30(3):198-206. PubMed ID: 20063323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down syndrome: prenatal risk assessment and diagnosis.
    Newberger DS
    Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost effectiveness analysis of prenatal screening of trisomy 21 by maternal serum markers (hCG)].
    Seror V; Moatti JP; Muller F; Le Gales C; Boue A
    J Gynecol Obstet Biol Reprod (Paris); 1992; 21(8):915-22. PubMed ID: 1491137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the utilization of prenatal diagnosis.
    Benn PA; Egan JF; Fang M; Smith-Bindman R
    Obstet Gynecol; 2004 Jun; 103(6):1255-60. PubMed ID: 15172861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-benefit analysis of prenatal detection of Down syndrome and neural tube defects in older mothers.
    Sadovnick AD; Baird PA
    Am J Med Genet; 1981; 10(4):367-78. PubMed ID: 6460445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AFP and age screening for Down syndrome.
    Wald N; Cuckle H
    Am J Med Genet; 1988 Sep; 31(1):197-209. PubMed ID: 2464930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current methods of prenatal screening for Down syndrome and other fetal abnormalities.
    Saller DN; Canick JA
    Clin Obstet Gynecol; 2008 Mar; 51(1):24-36. PubMed ID: 18303497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Down's syndrome. Data do not support study's claim.
    Norgaard-Pedersen B
    BMJ; 2000 Sep; 321(7263):763; author reply 764-5. PubMed ID: 10999925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.